Drug Development.

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's Disease (AD) is characterized by tau pathology accumulation, leading to neurodegeneration.
• Pathological tau spreads neuron-to-neuron via extracellular species.
• Antibodies targeting extracellular tau are a potential therapeutic strategy for AD.

Purpose of the Study:

• To characterize the preclinical profile of MK-2214, a novel antibody targeting phosphorylated serine 413 (pS413) tau.
• To evaluate MK-2214's potential as a therapeutic agent for Alzheimer's Disease.

Main Methods:

• Binding assays to assess MK-2214 specificity, selectivity, and potency for pS413 tau.
• Immunoassays using human brain and CSF samples to determine binding patterns.
• In vitro cell-based seeding models and in vivo mouse models to evaluate efficacy.
• Pharmacokinetic (PK) studies in nonhuman primates (NHP).

Main Results:

• MK-2214 demonstrated high potency and specificity for pS413 tau found in AD brains.
• Effective binding of extracellular tau species in human CSF samples at subnanomolar potency.
• Significant reduction in tau pathology in vitro and in vivo seeding studies.
• PK studies in NHP revealed an extended half-life for MK-2214 compared to traditional antibodies.

Conclusions:

• Preclinical data support MK-2214's favorable therapeutic profile for AD.
• MK-2214 shows potential to reduce extracellular tau spread and slow AD progression.
• The preclinical profile supports the clinical development of MK-2214 as an optimal tau antibody.